生物谷(833266) - 2023 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of ¥622,338,700.67, representing a year-on-year increase of 5.96%[5] - The net profit attributable to shareholders was -¥11,723,316.76, a reduction in loss by ¥37,445,495.70 compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥22,575,442.44, with a year-on-year loss reduction of ¥54,498,661.03[5] - Basic earnings per share were -¥0.09, an improvement of 77.50% from -¥0.40 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were ¥1,236,498,360.78, a decrease of 0.64% year-on-year[5] - Shareholders' equity attributable to the company was ¥999,713,684.94, down 1.16% from the previous year[5] - The company's capital stock decreased by 3.12% to ¥124,000,007.00[5] Market Development - The company increased efforts in market development and brand promotion, contributing to revenue growth[6] Other Income and Provisions - Other income decreased by ¥23,597,900.00 to ¥12,536,500.00 due to reduced government subsidies[7] - The company recognized a bad debt provision of ¥43,690,000.00, down from ¥89,950,000.00 in the previous year[8]